Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Lowers PT on Insulet Corporation Ahead of 4Q12 Results

Share:
Related PODD
Oppenheimer Reiterates Rating, Lowers Price Target On Insulet As New Management Begins Executing Plan
Mid-Morning Market Update: Markets Jump; Family Dollar Profit Misses Estimates
Orgenesis is Leading the Paradigm Shift in Diabetes Treatment (NVO, ORGS, JNJ, PODD) (Small Cap Network)

In a report published Friday, Canaccord Genuity reiterated its Buy rating on Insulet Corporation (NASDAQ: PODD), but slightly lowered its price target from $29.00 to $28.00.

Canaccord Genuity noted, “We are fine-tuning our model heading into the Q4/12 results to account for the expected impact of competitive bidding on Insulet's Neighborhood Diabetes (NDI) supplies business. Specifically, given management's commentary about the expected impact on its Medicare business, we have conservatively removed all revenues that could be impacted by competitive bidding from our estimates.”

Insulet Corporation closed on Thursday at $21.18.

Latest Ratings for PODD

DateFirmActionFromTo
Jan 2015Leerink SwannMaintainsOutperform
Jan 2015JP MorganDowngradesOverweightNeutral
Jan 2015JefferiesMaintainsBuy

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (PODD)

Around the Web, We're Loving...

Get Benzinga's Newsletters